Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.43 |
| ▸ | PARP11 | Q9NR21 | 2/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6361357 | 0.92 | MAPT (0.45) | PARP10PARP11PDPK1PARP1MAPT | |
| SCHEMBL8137134 | 0.82 | TSHR (0.44) | PARP10PARP11PDPK1PARP1MAPT | |
| Indoline SCHEMBL10723456 | 0.82 | HTR2C (0.50) | PARP10PARP11PDPK1PARP1MAPT | |
| Indoline SCHEMBL27828673 | 0.82 | HTR2C (0.50) | PARP10PARP11PDPK1PARP1MAPT | |
| Indoline SCHEMBL11401846 | 0.82 | HTR2C (0.50) | PARP10PARP11PDPK1PARP1MAPT | |
| Indoline SCHEMBL29360339 | 0.80 | — | — | |
| Indoline SCHEMBL5629 | 0.80 | — | — | |
| Indoline SCHEMBL17746180 | 0.78 | PARP10 (0.50) | PARP10PARP11PDPK1PARP1MAPT | |
| Indoline SCHEMBL23295083 | 0.78 | HTR2C (0.50) | PARP10PARP11PDPK1PARP1MAPT | |
| Indoline SCHEMBL3905169 | 0.78 | HTR2C (0.50) | PARP10PARP11PDPK1PARP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010047737-A2 | ANTIMICROBIAL INDOLINE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. (KY) | 2010-04-29 | — | — | WO | disclosed |
| US-20100069441-A1 | ANTIMICROBIAL INDOLINE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | GORDEEV MIKHAIL FEDOROVICH | 2010-03-18 | — | — | US | disclosed |
| US-7435751-B2 | 7-Fluoro-1,3-dihydro-indol-2-one oxazolidinones as antibacterial agents | JOSYULA VARA PRASAD VENKATA NAGENDRA | 2008-10-14 | — | — | US | disclosed |
| EP-1869030-A1 | 7-FLUORO-1,3-DIHYDRO-INDOL-2-ONE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | Pharmacia & Upjohn Company LLC (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006106427-A1 | 7-FLUORO-1,3-DIHYDRO-INDOL-2-ONE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-10-12 | — | — | WO | disclosed |
| US-20060229349-A1 | 7-Fluoro-1,3-dihydro-indol-2-one oxazolidinones as antibacterial agents | JOSYULA VARA PRASAD V N | 2006-10-12 | — | — | US | disclosed |
| US-6972286-B2 | Oxazolidinones having a benzannulated 6- or 7-membered heterocycle | PHARMACIA AND UPJOHN COMPANY (US) | 2005-12-06 | — | — | US | disclosed |
| US-20040186293-A1 | Oxazolidinones having a benzannulated 6- or 7-membered heterocycle | JOHNSON PAUL D (US) | 2004-09-23 | — | — | US | disclosed |
| US-20040176609-A1 | Oxazolidinones having a benzannulated 6- or 7-membered heterocycle | JOHNSON PAUL D (US) | 2004-09-09 | — | — | US | disclosed |
| EP-1337530-A1 | OXAZOLIDINONES HAVING A BENZANNULATED 6-OR 7-MEMBERED HETEROCYCLE AS ANTIBACTERIAL AGENTS | Pharmacia & Upjohn Company (US) | 2003-08-27 | — | — | EP | disclosed |
| US-20020133021-A1 | Oxazolidinones having a benzannulated 6- or 7-membered heterocycle | PHARMACIA & UPJOHN COMPANY | 2002-09-19 | — | — | US | disclosed |
| WO-2002059115-A1 | OXAZOLIDINONES HAVING A BENZANNULATED 6-OR 7-MEMBERED HETEROCYCLE AS ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| EP-0648119-A1 | 5'-INDOLINYL OXAZOLIDINONES USEFUL AGAINST $i(MYCOBACTERIUM TUBERCULOSIS) | THE UPJOHN COMPANY (US) | 1995-04-19 | — | — | EP | disclosed |
| WO-1994001110-A1 | 5'-INDOLINYL OXAZOLIDINONES USEFUL AGAINST $i(MYCOBACTERIUM TUBERCULOSIS) | THE UPJOHN COMPANY (US) | 1994-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229349-A1 | 7-Fluoro-1,3-dihydro-indol-2-one oxazolidinones as antibacterial agents | OXA1L, MRPL21, FOXM1 | PARP10 2108/4885PARP11 1467/4885PDPK1 439/4885 |
| US-20020133021-A1 | Oxazolidinones having a benzannulated 6- or 7-membered heterocycle | OXA1L, CDK16, MT-ND6 | PARP10 1787/4885PARP11 3214/4885PDPK1 2148/4885 |
| US-20100069441-A1 | ANTIMICROBIAL INDOLINE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | IDO1, IDO2, INMT | PARP10 3391/4885PARP11 2878/4885PDPK1 1245/4885 |
| US-20040186293-A1 | Oxazolidinones having a benzannulated 6- or 7-membered heterocycle | OXA1L, CDK16, MT-ND6 | PARP10 1787/4885PARP11 3214/4885PDPK1 2148/4885 |
| US-20040176609-A1 | Oxazolidinones having a benzannulated 6- or 7-membered heterocycle | OXA1L, CDK16, MT-ND6 | PARP10 1787/4885PARP11 3214/4885PDPK1 2148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.